Crystal Pike
Education
M.B.A., MIT Sloan School of Management; B.A., economics, Mount Holyoke College
Summary of Experience
Ms. Pike applies her expertise in health economics, statistics, and large administrative claims and transaction-level databases to help resolve complex litigation and strategic business questions in a variety of contexts, including matters involving the False Claims Act, Anti-Kickback Statute, and Controlled Substance Act. She has performed economic analyses and presented findings to US Attorney's Office investigators in numerous cases involving allegations of off-label promotion, kickback, and pricing issues. Ms. Pike also applies economic theory and empirical estimation methods in a variety of product liability, breach of contract, intellectual property, and transfer-pricing engagements. She has extensive experience in developing flexible damages models for real-time use in high-stakes negotiations.
Ms. Pike has been instrumental in developing bespoke suspicious order monitoring programs; building internal analytical programs to assess the risk of theft or diversion; and assisting manufacturers, wholesalers, and pharmacies in responding to government investigations and/or lawsuits related to controlled substance distribution and dispensing. She has managed a range of health care cases involving analysis of future lost profits; economic analysis of physician payment structures under capitation; studies of the cost effectiveness, budget impacts, and direct and indirect costs of illness associated with a variety of diseases; and pricing analyses for large multinational corporations across numerous industries. Ms. Pike has published numerous articles on related topics in health care economics and clinical journals.
- Controlled Substance Monitoring and Effective Controls Against Diversion: Investigations and Settlements
- Controlled Substance Suspicious Order Monitoring Modeling
- Daiichi Sankyo and Ranbaxy Laboratories Damages Arbitration
- Humana Inc. v. Celgene Corp.
- In re: Lamictal Direct Purchaser Antitrust Litigation
- In re: Optical Disk Drive Products Antitrust Litigation
- Pharmaceutical Off-Label Promotion & Kickbacks Settlements
- United States of America et al ex rel Brown v Celgene Corp
-
Tracing The Path To Health Care Investigation Settlements
Law 360, April 17, 2017
2017 -
Legal Considerations in a World of Comparative Effectiveness Research
Decision Making in a World of Comparative Effectiveness Research
2017Kalb P, Greenberg P, Pike C
-
Comparative Effectiveness Research: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies
Decision Making in a World of Comparative Effectiveness Research
2017Piech C, Lefebvre P, Pike C
-
Viewing Recent Opioid Regulations In Context
Law360, April 1, 2016
2016 -
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
J Clin Psychiatry 2015 Feb;76(2):155-73
2015Greenberg P, Fournier A, Sisitsky T, Pike C, Kessler R
-
Societal cost of rheumatoid athritis patients in the US
Curr Med Res Opin. 2010 Jan;26(1):77-90
2010Birnbaum H, Pike C, Kaufman R, Maynchenko M, Kidolezi Y, Cifaldi M
-
Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature
Expert Opin Pharmacother. 2009 Feb;10(2):255-69
2009Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M
-
Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis
J Occup Environ Med. 2009 Oct;51(10):1167-76
2009Birnbaum H, Pike C, Kaufman R, Cifaldi M
-
The Economic Consequences of Irritable Bowel Syndrome: A US Employer Perspective
Arch Intern Med. 2003 Apr 28;163(8):929-35.
2003Leong SA, Barghout V, Birnbaum HG, Pike C, Ben-Hamadi R, Frech F, Ofman JJ
-
Productivity Loss Due to Irritable Bowel Syndrome—Reply
Arch Intern Med. 2003;163(18):2249-2250
2003Greenberg P, Birnbaum H, Leong S, Pike C, Ben-Hamadi R, Barghout V, Frech F, Ofman J
-
April 27, 2021
-
September 14, 2022